MiNK Therapeutics, Inc.
INKT· Nasdaq
INKTMiNK Therapeutics, Inc.
Filed Aug 13, 2024 · 10-Q · 44 days after period end · 0000950170-24-096142
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$2.70M | -$6.20M | -$6.11M | -$6.34M |
| EPS Diluted | -$0.07 | -$0.18 | -$0.18 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MiNK Therapeutics, Inc. · CIK 1840229 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end
